Chengdu Olymvax Biopharmaceuticals Inc. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 370.78 million compared to CNY 284.76 million a year ago. Revenue was CNY 370.78 million compared to CNY 284.76 million a year ago.

Net income was CNY 40.18 million compared to CNY 77.67 million a year ago. Basic earnings per share from continuing operations was CNY 0.0991 compared to CNY 0.2053 a year ago. Diluted earnings per share from continuing operations was CNY 0.0991 compared to CNY 0.2053 a year ago.